What does ULISSES™ do?

- ULISSES™ greatly expands the window of time that an organ or limb can remain viable for a transplant or re-attachment operation.
- Every 30 seconds a patient dies from diseases that could be treated with vascularized tissue replacement.
- With its ability to preserve and resuscitate vascularized tissue—organs and limbs—for more than 24-hours, ULISSES™ removes the geographic limitations associated with transportation.
- ULISSES™ helps remove time from the transplant equation and offers hope to patients awaiting organ transplants.

How long can ULISSES™ keep an organ/limb alive?

- ULiSSES™ is designed to preserve and resuscitate vascularized tissue—organs and limbs—for more than 24-hours.

Why does extending the viability of an organ from 4-hours to 24-hours make such a difference?

- **More Organs:** More donated organs will be viable because there's more time to reach patients.
- **Better Matches:** With more organs available, surgeons are able to select a better match, rather than settling for a possible match.
- **Fewer Rejections:** With more time, organs are in better condition at transplantation, rather than on the edge of viability.

Why isn’t ULISSES™ already on the market?

- We are continuing to move through the research process and are working to obtain the FDA’s approval of ULiSSES™ in early clinical use.

How will you use the funds received through the GoFundMe effort?

- The funds raised will allow VPS to get more ULiSSES™ devices into the field for testing, and get them there sooner. This will provide the diversity and volume of data needed to secure early FDA clearance.

How exactly does ULISSES™ work?

- ULISSES™ uses only a small oxygen cylinder for power and active perfusion, to allow transport of organs or limbs anywhere in the world.
- It is highly portable, single-use/disposable, simple to operate, light-weight, and inexpensive.
- It can easily be transported in a commercial airliner, stored in an overhead compartment, or under the seat.
- On the battlefield, the ULISSES™ device offers a flexible casing option using the same fluid carried by medics in common IV bags, to preserve an avulsed hand, arm, or leg until a warfighter can have it reattached at a regular hospital.
What is the current method of organ preservation and limb preservation? / Why is the ULiSSES™ better for preserving limbs than the current technology?

- Currently, the most commonly used and accepted method for organ transport and preservation is an ice chest, which offers no oxygenation, only insulation. Ice—dry, frozen or Blu—is used in the cooler to slow down the deterioration process.
- ULiSSES™ perfuses tissue with oxygenated fluid, allowing an organ to be viable for more than 24 hours. This enables the organ to be transported to anywhere in the world to a patient awaiting treatment or transplant.
- ULiSSES™ dramatically increases the time available for transplant operations.

How much will a patient have to pay to use one of these devices?

- The cost per patient will vary depending on their insurance coverage.

When will this device come out on the open market?

- This will depend on obtaining the FDA's clearance to make ULiSSES™ available to the public, anticipated to occur prior to the close of 2019.

What has to happen before you can start selling these?

- We must move through the research process and obtain the FDA's permission to get the ULiSSES™ device into early clinical use. As soon as the FDA allows, ULiSSES™ will apply for clearance to make the device available to the public.
- Even so at this stage, ULiSSES™ is fully functional for research purposes.

What/who is VPS? How is it associated with the ULiSSES™ device?

- Vascular Perfusion Solutions, Inc. (VPS) is a development and early-stage company, formed for the purpose of commercializing new, unique, and innovative Oxygenated Perfusion Solutions for the body's limbs, organs, and other vascularized tissues.
- The primary goal of VPS is to extend life, and enhance its quality. In the development of ULiSSES™, we aim to improve the quality-of-life of patients awaiting organ transplant by removing obstacles that can impede or delay their treatment and healing.

What kind of research will you be conducting?

- The ULiSSES™ device has already been successfully tested in small animal studies. The next step is to conduct large animal studies, followed by human testing. This will provide the data needed for early FDA submission to secure FDA clearance.